MDWD.NASDAQMediwound LTD

Form 4: MediWound Director Nachum Shamir Acquires Shares

Sentiment:

Statement of Changes in Beneficial Ownership


MediWound Ltd. Director Nachum Shamir has acquired ordinary shares and holds various derivative securities, as detailed in a recent SEC Form 4 filing.

Summary

  • Director Nachum Shamir acquired 175 ordinary shares at $13.975 and 5,825 ordinary shares at $14 on June 3, 2026.
  • Following these transactions, Shamir beneficially owns 49,990 ordinary shares directly and an additional 5,825 ordinary shares directly.
  • The filing also lists existing beneficial ownership of 1,200 ordinary shares.
  • Shamir holds several derivative securities, including Series A Warrants and various stock options with different exercise prices and expiration dates.
  • A Power of Attorney was filed, appointing Yaron Meyer as attorney-in-fact for executing SEC filings.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine share transactions by a director and a power of attorney, without new financial or strategic information.

Positives

  • Director Nachum Shamir has increased his direct beneficial ownership of ordinary shares.
  • The acquisition of shares by a director can be interpreted as a positive signal of confidence in the company.

Future Outlook

This filing is a statement of changes in beneficial ownership and does not contain forward-looking statements or guidance regarding future financial performance.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insiders and directors, providing transparency on their share transactions. Such filings are crucial for investors monitoring insider confidence and potential trading activity within a company.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Power of AttorneyNachum Shamir appointed Yaron Meyer as attorney-in-fact to execute and file Forms 3, 4, and 5 with the SEC.03/18/2026Ensures compliance with Section 16(a) reporting requirements for insider transactions.

Stakeholder Impact

  • Shareholders: Gain insight into director's shareholdings and transactions, which can inform investment decisions.
  • Management: The filing confirms adherence to regulatory reporting requirements for insider transactions.

Key Dates

DateDescription
06/03/2026Transaction Date for acquisition of ordinary shares.
06/04/2026Date of signature for Power of Attorney.
03/18/2026Date of execution for Power of Attorney.

Keywords

SEC Form 4, MediWound Ltd., MDWD, Director, Beneficial Ownership, Ordinary Shares, Derivative Securities, Stock Options, Warrants, Insider Trading

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.